180 Life Sciences Files S-1 for Securities Offering

TL;DR

180 Life Sciences filed an S-1, looks like they're raising cash.

AI Summary

180 Life Sciences Corp. filed an S-1 registration statement on July 19, 2024, indicating plans to offer securities. The company, formerly known as KBL Merger Corp. IV, is incorporated in Delaware and operates in the pharmaceutical preparations sector. Its principal executive offices are located in Palo Alto, California.

Why It Matters

This S-1 filing signals 180 Life Sciences Corp.'s intention to raise capital through the sale of securities, which could impact its future operations and stock performance.

Risk Assessment

Risk Level: medium — As a company filing an S-1, it is typically seeking to raise capital, which can involve inherent risks related to market conditions and the success of the offering.

Key Numbers

• 333-280912 — SEC File Number (Identifies the specific SEC filing)
• 0001690080 — Central Index Key (Unique identifier for the company in SEC filings)

Key Players & Entities

• 180 Life Sciences Corp. (company) — Registrant
• KBL Merger Corp. IV (company) — Former company name
• July 19, 2024 (date) — Filing date
• Delaware (jurisdiction) — State of incorporation
• Palo Alto, CA (location) — Principal executive offices
• Blair Jordan (person) — Interim Chief Executive Officer

FAQ

Key Financial Figures

• $0.0001 — on of shares of common stock, par value $0.0001 per share (the “ Common Stock &rd
• $2.39 — sing sale price of our Common Stock was $2.39 per share. There is no established publ
• $2 million — policy, and seeking damages of at least $2 million in compensatory damages, together with

Filing Documents

• ea0209604-s1_180life.htm (S-1) — 529KB
• ea020960401ex23-1_180life.htm (EX-23.1) — 3KB
• ea020960401ex-fee_180life.htm (EX-FILING FEES) — 12KB
• image_001.jpg (GRAPHIC) — 4KB
• 0001213900-24-063026.txt ( ) — 551KB

Risk Factors

Risk Factors 9 Incorporation by Reference 24

Use of Proceeds

Use of Proceeds 25 Capitalization 26

Dilution

Dilution 27 Dividend Policy 29 Plan of Distribution 30

Description of Capital Stock

Description of Capital Stock 32

Description of Securities We Are Offering

Description of Securities We Are Offering 35 Legal Matters 38 Experts 38 Where You Can Find More Information 38 i Our logo and some of our trademarks and tradenames are used in this prospectus. This prospectus also includes trademarks, tradenames and service marks that are the property of others. Solely for convenience, trademarks, tradenames and service marks referred to in this prospectus may appear without the ®, ™ and SM symbols. References to our trademarks, tradenames and service marks are not intended to indicate in any way that we will not assert to the fullest extent under applicable law our rights or the rights of the applicable licensors if any, nor that respective not intend the use or display of other companies’ trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. The market data and certain other statistical information used throughout this prospectus are based on independent industry publications, reports by market research firms or other independent sources that we believe to be reliable sources; however, we have not commissioned any of the market or survey data that is presented in this prospectus. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. We are responsible for all of the disclosures contained in this prospectus, and we believe these industry publications and third-party research, surveys and studies are reliable, provided that we have not commissioned any such information. While we are not aware of any misstatements regarding any third-party information presented in this prospectus, their estimates, in particular, as they

View Full Filing

View this S-1 filing on SEC EDGAR